Literature DB >> 24561542

The perioperative educational program for improving upper arm dysfunction in patients with breast cancer: a controlled trial.

Fumiko Sato1, Takanori Ishida, Noriaki Ohuchi.   

Abstract

Most patients who undergo breast cancer surgery suffer from impairment of upper extremity function. In this study, we investigated the effectiveness of a perioperative educational program for improving upper arm dysfunction in patients with breast cancer. This longitudinal controlled study was conducted between January 2010 and July 2012. Participants comprised 149 patients with primary breast cancer before operation, allocated to intervention and control groups. Intervention comprised a 3-month educational program on monitoring arm function and exercises for preventing shoulder dysfunction and lymphedema. The control group received routine care from on-site staffs. Of the 149 patients analyzed, 69 underwent axillary lymph node dissection (ALND), and 80 underwent sentinel lymph node biopsy (SLNB). The intervention group included 39 patients with ALND and 51 patients with SLNB, while the control group included 30 patients with ALND and 29 patients with SLNB. Arm girth, shoulder range of motion (ROM), and grip strength were measured before surgery and at 1 week, 1 month and 3 months postoperatively. Self-reported questionnaires, the Subjective Perception of Post-Operative Functional Impairment of the Arm (SPOFIA) and the Disabilities of the Arm, Shoulder and Hand (DASH), were administered at the same time points. Among the variables examined, only SPOFIA and grip strength were significantly improved in the intervention group with ALND. In contrast, the perioperative educational program caused no significant improvement for the patients who underwent the surgery with SLNB. Thus, the present program improves the postoperative upper arm function and discomfort in breast cancer patients who undergo surgery with ALND.

Entities:  

Mesh:

Year:  2014        PMID: 24561542     DOI: 10.1620/tjem.232.115

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  6 in total

Review 1.  systematic review of multimodal prehabilitation in breast cancer.

Authors:  Kellie Toohey; Maddison Hunter; Karen McKinnon; Tamara Casey; Murray Turner; Suzanne Taylor; Catherine Paterson
Journal:  Breast Cancer Res Treat       Date:  2022-10-21       Impact factor: 4.624

2.  Assessment Tools of Patient Competences: The Spanish Version of the R-NPQ and Three Practical Cases in Women with Breast Cancer and Persistent Pain.

Authors:  María Torres-Lacomba; Beatriz Navarro-Brazález; Javier Bailón-Cerezo; Fernando Vergara-Pérez; Irene de la Rosa-Díaz; Virginia Prieto-Gómez
Journal:  Int J Environ Res Public Health       Date:  2021-04-22       Impact factor: 3.390

3.  Preliminary Study on the Effect of an Early Physical Therapy Intervention after Sentinel Lymph Node Biopsy: A Multicenter Non-Randomized Controlled Trial.

Authors:  María Jesús Muñoz-Fernández; Esther M Medrano-Sánchez; Beatriz Ostos-Díaz; Rocío Martín-Valero; Carmen Suárez-Serrano; María Jesús Casuso-Holgado
Journal:  Int J Environ Res Public Health       Date:  2021-01-31       Impact factor: 3.390

4.  Thematic trends and knowledge structure map of sentinel lymph node biopsy for breast cancer: a bibliometric analysis from 2010 to 2019.

Authors:  Yujie Huo; Ting Fan; Si Chen; Qiannan Liu; Yue Fang; Fan Yao
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

5.  The Study of Validity and Reliability of the SPOFIA Scale in Patients With Postoperative Breast Cancer.

Authors:  Havva Bozdemir; Dilek Aygin
Journal:  Breast Cancer (Auckl)       Date:  2019-10-21

6.  Early Physical Rehabilitation after Sentinel Lymph Node Biopsy in Breast Cancer: Is It Feasible and Safe?

Authors:  Beatriz Ostos-Díaz; María Jesús Casuso-Holgado; María Jesús Muñoz-Fernández; Ana F Carazo; Rocío Martín-Valero; Esther M Medrano-Sánchez
Journal:  Int J Environ Res Public Health       Date:  2020-11-12       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.